000280972 001__ 280972
000280972 005__ 20250918102645.0
000280972 0247_ $$2doi$$a10.1016/j.neurobiolaging.2025.07.007
000280972 0247_ $$2pmid$$apmid:40712373
000280972 0247_ $$2ISSN$$a0197-4580
000280972 0247_ $$2ISSN$$a1558-1497
000280972 037__ $$aDZNE-2025-01054
000280972 041__ $$aEnglish
000280972 082__ $$a610
000280972 1001_ $$0P:(DE-2719)9002420$$aLeone, Riccardo$$b0$$eFirst author$$udzne
000280972 245__ $$aWhite matter hyperintensities contribute to early cortical thinning in addition to tau in aging.
000280972 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000280972 3367_ $$2DRIVER$$aarticle
000280972 3367_ $$2DataCite$$aOutput Types/Journal article
000280972 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1758106902_31854
000280972 3367_ $$2BibTeX$$aARTICLE
000280972 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280972 3367_ $$00$$2EndNote$$aJournal Article
000280972 520__ $$aWhite matter hyperintensities (WMH) are associated with cortical thinning in distant brain regions. However, it is currently unclear how WMH affect neurodegeneration in early Alzheimer's disease (AD). Here, we investigated associations between WMH and cortical thickness in temporal regions involved in early AD (AD cortical signature), while correcting for regional amyloid and tau accumulation assessed by PET. We performed cross-sectional (n = 551), and longitudinal (n = 125) analyses in older adults without dementia, also stratified by amyloid positivity. We evaluated WMH volume - as a measure of the global burden of WMH-related cerebrovascular pathology (GB-WMH) - and investigated the role of deep versus periventricular WMH. We also tested whether a higher focal burden of WMH in specific tracts connected to AD signature regions (FB-WMH) would lead to greater cortical thinning than expected solely from GB-WMH. We performed exploratory analyses in other brain regions to check the specificity of our findings to the temporal AD signature. GB-WMH damage, especially involving periventricular WMH, was cross-sectionally (not longitudinally) associated with cortical thinning in the fusiform, inferior and middle temporal gyri. Stronger associations were found in amyloid-positive individuals, including for the entorhinal cortex. Effects were mostly confined to regions of the temporal AD signature. FB-WMH did not yield higher cortical thinning than expected solely by GB-WMH. Cerebrovascular disease is associated with cortical thinning of temporal regions involved in early AD. Interventions aimed at improving cerebrovascular health might help to mitigate neurodegeneration in these regions.
000280972 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280972 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280972 650_7 $$2Other$$aAD
000280972 650_7 $$2Other$$aAlzheimer’s Disease
000280972 650_7 $$2Other$$aAmyloid
000280972 650_7 $$2Other$$aCopathologies
000280972 650_7 $$2Other$$aCortical thickness
000280972 650_7 $$2Other$$aDisconnections
000280972 650_7 $$2Other$$aTau
000280972 650_7 $$2Other$$aWMH
000280972 7001_ $$0P:(DE-2719)9001475$$aKobeleva, Xenia$$b1$$eLast author$$udzne
000280972 7001_ $$aInitiative, Alzheimer's Disease Neuroimaging$$b2$$eCollaboration Author
000280972 773__ $$0PERI:(DE-600)1498414-3$$a10.1016/j.neurobiolaging.2025.07.007$$gVol. 155, p. 66 - 77$$p66 - 77$$tNeurobiology of aging$$v155$$x0197-4580$$y2025
000280972 8564_ $$uhttps://pub.dzne.de/record/280972/files/DZNE-2025-01054%20SUP.docx
000280972 8564_ $$uhttps://pub.dzne.de/record/280972/files/DZNE-2025-01054_Restricted.pdf
000280972 8564_ $$uhttps://pub.dzne.de/record/280972/files/DZNE-2025-01054_Restricted.pdf?subformat=pdfa$$xpdfa
000280972 909CO $$ooai:pub.dzne.de:280972$$pVDB
000280972 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002420$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000280972 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001475$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000280972 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280972 9141_ $$y2025
000280972 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-13$$wger
000280972 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROBIOL AGING : 2022$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000280972 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-13
000280972 9201_ $$0I:(DE-2719)1011001$$kClinical Research (Bonn)$$lClinical Research Coordination$$x0
000280972 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Research Platform (CRP)$$x1
000280972 980__ $$ajournal
000280972 980__ $$aVDB
000280972 980__ $$aI:(DE-2719)1011001
000280972 980__ $$aI:(DE-2719)1011103
000280972 980__ $$aUNRESTRICTED